01—Abstract
Summary
Summary of the 8-K filed March 4, 2024. Cited figures are marked; the original filing is the authoritative source.
Elevance Health, Inc. (ELV) filed an 8-K on March 4, 2024, primarily to reaffirm its full-year 2024 financial guidance and to announce positive developments regarding its Medicare Advantage Star Ratings.
The company reiterated its net income guidance to be greater than $34.29a per diluted share, and adjusted net income to be greater than $37.10 per diluted share, after accounting for approximately $2.81 per diluted share in unfavorable items. Furthermore, Elevance Health received notification from the Centers for Medicare & Medicaid Services (CMS) that four of its Medicare Advantage contracts received an updated, higher Star Rating.
This positive revision means that the company now expects approximately 49% of its Medicare Advantage members to be enrolled in plans rated at least 4-Star for the 2024 Star Ratings (which impacts payment year 2025 revenue). The company estimates this reconsideration will add approximately $190 millionb to its payment year 2025 revenue, a notable benefit for future financial performance.
02—Key points
Key Highlights
- Reaffirms 2024 full-year net income guidance: greater than $34.29 per diluted share.
- Reaffirms 2024 full-year adjusted net income guidance: greater than $37.10 per diluted share.
- Four Medicare Advantage contracts received higher CMS Star Ratings after reconsideration.
- Expects approximately 49% of Medicare Advantage members to be in plans rated 4-Star or higher for 2024 (impacting 2025 revenue).
- Estimates a positive financial benefit of approximately $190 million on payment year 2025 revenue due to the Star Rating update.
03—Questions
Frequently Asked Questions
What is the impact of the updated Medicare Advantage Star Ratings on Elevance Health's financials?
The updated Star Ratings for four Medicare Advantage contracts are expected to result in approximately 49% of the company's Medicare Advantage members being in plans rated 4-Star or higher for the 2024 Star Ratings period. This is estimated to generate an additional $190 million in revenue for payment year 2025.
Does the company's 2024 earnings guidance include the impact of the Star Rating improvement?
The 8-K states the company reaffirms its 2024 net income guidance. The financial benefit from the Star Rating reconsideration is estimated for payment year 2025 revenue, suggesting it is not directly factored into the current 2024 earnings guidance, but rather impacts future revenue streams.
What are the key unfavorable items impacting the 2024 net income guidance?
The filing mentions approximately $2.81 per diluted share of net unfavorable items affecting the 2024 net income guidance. However, the specific nature of these unfavorable items is not detailed in this particular 8-K filing.
04—Continue